Bone Biologics (BBLG) Common Equity (2010 - 2025)

Bone Biologics (BBLG) has 16 years of Common Equity data on file, last reported at $5.4 million in Q4 2025.

• Common Equity for Q4 2025 came in at $5.4 million, up 54.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.4 million (up 54.37% YoY), and the FY2025 annual result was $5.4 million, up 54.37% from the prior year.
• Common Equity eased to $5.4 million in Q4 2025 per BBLG's latest filing, from $6.0 million in the prior quarter.
• Over five years, Common Equity peaked at $6.6 million in Q2 2025 and troughed at -$15.1 million in Q3 2021.
• A 5-year average of $1.7 million and a median of $3.8 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2023: Common Equity soared 148.02% in 2021, then tumbled 54.09% in 2023.
• A 5-year view of Common Equity shows it stood at $6.6 million in 2021, then declined by 9.55% to $5.9 million in 2022, then tumbled by 51.13% to $2.9 million in 2023, then grew by 19.86% to $3.5 million in 2024, then jumped by 54.37% to $5.4 million in 2025.
• Business Quant data shows BBLG's Common Equity at $5.4 million in Q4 2025, $6.0 million in Q3 2025, and $6.6 million in Q2 2025.